KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Liabilities and Shareholders Equity: 2017-2024

Historic Liabilities and Shareholders Equity for Amneal Pharmaceuticals (AMRX) over the last 8 years, with Dec 2024 value amounting to $3.5 billion.

  • Amneal Pharmaceuticals' Liabilities and Shareholders Equity rose 4.01% to $3.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $13.9 billion, marking a year-over-year decrease of 0.08%. This contributed to the annual value of $3.5 billion for FY2024, which is 0.83% up from last year.
  • Amneal Pharmaceuticals' Liabilities and Shareholders Equity amounted to $3.5 billion in FY2024, which was up 0.83% from $3.5 billion recorded in FY2023.
  • In the past 5 years, Amneal Pharmaceuticals' Liabilities and Shareholders Equity ranged from a high of $4.0 billion in FY2020 and a low of $3.5 billion during FY2023.
  • Over the past 3 years, Amneal Pharmaceuticals' median Liabilities and Shareholders Equity value was $3.5 billion (recorded in 2024), while the average stood at $3.6 billion.
  • As far as peak fluctuations go, Amneal Pharmaceuticals' Liabilities and Shareholders Equity grew by 9.28% in 2020, and later declined by 8.60% in 2023.
  • Yearly analysis of 5 years shows Amneal Pharmaceuticals' Liabilities and Shareholders Equity stood at $4.0 billion in 2020, then decreased by 1.66% to $3.9 billion in 2021, then decreased by 3.56% to $3.8 billion in 2022, then dropped by 8.60% to $3.5 billion in 2023, then rose by 0.83% to $3.5 billion in 2024.